Evaluation of neurotoxic potential by use of in vitro systems

Bibliography

• GOLDBERG AM: An approach to the development of in vitro toxicological methods. Food Chem. Toxicol. (1985) 23:205–208.
   PubMed Web of Science ®Google Scholar
• SCALA RA: Theoretical approaches to validation. In: In vitro Toxicology Approaches to Validation. Alternative Methods in Toxicology, Vol 5. AM Goldberg (Ed.), Mary Ann Liebert, New York, US (1987):1–10.
   Google Scholar
• WILLIAMS SP, DAVENPORT-JONES J, EGAN C et al. : Phase I of an in vitro neurotoxicological prevalidation trial. Toxicol. In Vitro (1994) 8:799–802.
   PubMed Web of Science ®Google Scholar
• LIEB K, TREFFURTH, HAMKE M et al. : Evaluation of the use of in vitro methodologies as tools for screening new compounds for potential in vivo toxicity. Toxicol. In Vitro (2001) 15:571–577.
   PubMed Web of Science ®Google Scholar
• ASCHNER M, SYVERSEN T: Neurotoxicology: principles and considerations of in vitro assessment. Altern. Lab. Anim. (2004) 32(4):323–327.
   PubMed Web of Science ®Google Scholar
• TIFFANY-CASTIGLIONI E, EHRICH M, DEES L et al. : Bridging the gap between in vitro and in vivo models for neurotoxicology. Toxicol. Sci. (1999) 51(2):178–183.
   PubMed Web of Science ®Google Scholar
• TIFFANY-CASTIGLIONI E: In vitro Neurotoxicology: Principles and Challenges. Humana Press, Inc., Totowa, NJ, USA (2004).
   Google Scholar
• HARRY GJ, BILLINGSLEY M, BRUININK A et al.: In vitro techniques for the assessment of neurotoxicity. Environ. Health Perspect. (1998) 106:131–158.
   PubMed Web of Science ®Google Scholar
• ARAQUE A, PEREA G: Glial modulation of synaptic transmission in culture. Glia (2004) 47(3):241–248.
   PubMed Web of Science ®Google Scholar
• HARRY GJ: Basic principles of disturbed CNS and PNS functions. In: Introduction to neurobehavioral toxicology: Food and environment. RJM Niesink, RMA Jaspers, LMV Kornet, JM van Ree, HA Tilson (Eds), CRC Press, Boca Raton, FL, USA (1999):115–162.
   Google Scholar
• PARDRIDGE W: Introduction to blood-brain barrier. Cambridge University Press, Cambridge, UK .
   Google Scholar
• PARDRIDGE WM: Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev. Drug Discov. (2002) 1(2):131–139.
   PubMed Web of Science ®Google Scholar
• TERASAKI T, OHTSUKI S, HORI S, TAKANAGA H, NAKASHIMA E, HOSOYA K: New approaches to in vitro models of blood-brain barrier drug transport. Drug Discov. Today (2003) 8(20):944–954.
   PubMed Web of Science ®Google Scholar
• TAHTI H, NEVALA H, TOIMELA T: Refining in vitro neurotoxicity testing - the development of blood-brain barrier models. Altern. Lab. Anim. (2003) 31:273–276.
   PubMed Web of Science ®Google Scholar
• HASELOFF RF, BLASIG IE, BAUER HC, BAUER H: In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro. Cell Mol. Neurobiol. (2005) 25(1):25–39.
   PubMed Web of Science ®Google Scholar
• SCHIERA G, SALA S, GALLO A et al. : Permeability properties of a three-cell type in vitro model of blood-brain barrier. J. Cell Mol. Med. (2005) 9(2):373–379.
   PubMed Web of Science ®Google Scholar
• WALUM E, NORDIN M, BECKMAN M, ODLAN L: Cellular methods for identification of neurotoxic chemicals and estimation of neurotoxicological risk. Toxicol. In Vitro (1993) 7:321–326.
   PubMed Web of Science ®Google Scholar
• BRUININK A, YU D, MAIER P: Shortterm assay for the identification of neurotoxic compounds and their liver derived stable metabolites. Toxicol. In Vitro (2002) 16:717–724.
   PubMed Web of Science ®Google Scholar
• HEIKKILA RE, HESS A, DUVOISIN RC: Dopaminergic neurotoxicity of 1-methyl-4- phenyl-1,2,5,6-tetrahydropyridine in mice. Science (1984) 224:1451–1453.
   PubMed Web of Science ®Google Scholar
• LANGSTON JW, FORNO LS, REBERT CS, IRWIN I: Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,5,6- tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. (1984) 292:390–394.
   PubMed Web of Science ®Google Scholar
• DESAGHER S, GLOWINSKI J, PREMONT J: Astrocytes protect neurons from hydrogen peroxide toxicity. J. Neurosci. (1996) 16:2553–2562.
   PubMed Web of Science ®Google Scholar
• DRINGEN R, PFEIFFER B, HAMPRECHT B: Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as a precursor for neuronal glutathione. J. Neurosci. (1999) 19:562–569.
   PubMed Web of Science ®Google Scholar
• GREENE LA, TISCHLER AS: Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. USA (1976) 73:2424–2428.
   PubMed Web of Science ®Google Scholar
• GUROFF G: PC12 cells as model of neuronal differentiation. In: Cell Culture in the Neurosciences. JE Bottenstein, G Sato, (Eds), Plenum Publishing, New York, US (1985):245–272.
   Google Scholar
• FUJITA K, LAZAROXICI P, GUROFF G: Regulation of the differentiation of PC-12 pheochromocytoma cells. Environ. Health Perspect. (1989) 80:127–142.
   PubMed Web of Science ®Google Scholar
• SHASTRY P, BASU A, RAJADHYAKSHA MS: Neuroblastoma cell lines - a versatile in vitro model in neurobiology. Int. J. Neurosci. (2001) 108(1–2):109–126.
   PubMed Web of Science ®Google Scholar
• SPENGLER BA, ROSS RA, BIEDLER JL: Differential drug sensitivity of human neuroblastoma cells. Cancer Treat. Rep. (1986) 70(8):959–965.
   PubMedGoogle Scholar
• HAMPRECH B: Structural, electrophysiological, biochemical and pharmacological properties of neuroblastoma-glioma cell hybrids in culture. Int. Rev. Cytol. (1977) 49:99–170.
   PubMedGoogle Scholar
• DURHAM HD, DAHROUGH S, CASHMAN S: Evaluation of the spinal cord neuron X neuroblastoma hybrid cell line NSC-34 as a model for neurotoxicity testing. Neurotoxicology (1993) 14:387–396.
   PubMed Web of Science ®Google Scholar
• BIGNAMI A, DAHL D, RUEGER DC: Glial fibrillary acidic proteins in normal cells and in pathological conditions. Adv. Cell Neurobiol. (1980) 1:285–309.
   Google Scholar
• COOKSON MR, PENTREATH VW: Alterations in the glial fibrillary acid protein content of primary astrocyte cultures for evaluation of glial cell toxicity. Toxicol. In Vitro (1994) 8:351–359.
   PubMed Web of Science ®Google Scholar
• STOPPINI L, BUCHS LA, MULLER D: A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods (1991) 37:173.
   Web of Science ®Google Scholar
• NORABERG J: Organotypic brain slice cultures: an efficient and reliable method for neurotoxicological screening and mechanistic studies. Altern. Lab. Anim. (2004) 32(4):329–337.
   Web of Science ®Google Scholar
• ABDEL-HAMID KM, TYMIANSKI M: Mechanisms and effects of intracellular calcium buffering on neuronal survival in organotypic hippocampal cultures exposed to anoxia/aglycemia or to excitotoxins. J. Neurosci. (1997) 17:3538–3553.
   PubMed Web of Science ®Google Scholar
• ADAMCHIK Y, FRANTSEVA MV, WEISSPAPIR M, CARLEN PL, PEREZ-VELAZQUEZ JL: Methods to induce primary and secondary traumatic damage in organotypic hippocampal slice cultures. Brain Res. Protocols (2000) 5:153–158.
   PubMedGoogle Scholar
• KRISTENSEN BW, NORABERG J, ZIMMER J: Comparison of excitotoxic profiles of ATPA, AMPA, KA and MNDA in organotypic hippocampal slice cultures. Brain Res. (2001) 917:21–44.
   PubMed Web of Science ®Google Scholar
• KRISTENSEN BW, NORABERG J, THIEBAUD P, KOUDELKA-HEP M, ZIMMER J: Biocompatibility of siliconbased arrays of electrodes coupled to organotypic hippocampal brain slice cultures. Brain Res. (2001) 896:1–17.
   PubMed Web of Science ®Google Scholar
• PENTREATH VW: Neurotoxicology in vitro. Taylor and Francis, London, UK (1999).
   Google Scholar
• SMITH SL, SADLER CJ, DODD CC et al. : The role of glutathione in the neurotoxicity of artemisinin derivatives in vitro. Biochemical Pharmacol. (2001) 61(4):409–416.
   PubMed Web of Science ®Google Scholar
• SCRENCI D, MCKEAGE MJ: Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. Oncol. Res. (1999) 11(6):287–293.
   PubMedGoogle Scholar
• DONZELLI E, CARFI M, MILOSO M, STRADA A, GALBIATI S, BAYSSAS M: Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J. Neurooncol. (2004) 67(1–2):65–73.
   Google Scholar
• RZESKI W, PRUSKIL S, MACKE A et al. : Anticancer agents are potent neurotoxins in vitro and in vivo. Ann. Neurol. (2004) 56:351–360.
   Google Scholar
• SLAMON N, WARD TH, BUTLER J, PENTREATH VW: Assessment of DNA damage in C6 glioma cells after antidepressant treatment using an alkaline comet assay. Arch. Toxicol. (2001) 75:243–250.
   PubMed Web of Science ®Google Scholar
• NOH JS, HYO JK, KIM EY et al. : Haloperidol-induced neuronal apoptosis: role of p38 and c-Jun-NH2-terminal protein kinase. J. Neurochem. (2002) 75:2327–2334.
   Web of Science ®Google Scholar
• SPAHR-SCHOPFER I, VUTSKITS L, TONI N, BUCHS PA, PARISI L, MULLER D: Differential neurotoxic effects of propofol on dissociated cortical cells and organotypic hippocampal cultures. Anesthesiology (2000) 92(5):1408–1417.
   PubMed Web of Science ®Google Scholar
• PAVONE A, CARDILE V: An in vitro study of new antiepileptic drugs and astrocytes. Epilepsia (2003) 44(Suppl. 10):34–39.
   Google Scholar
• GAO WQ, DYBDAL N, SHINSKY N et al. : Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann. Neurol. (1995) 38:30–37.
   PubMed Web of Science ®Google Scholar
• ARAUJO IM, AMBROSIO AF, LEAL EC et al. : Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepin, and two new putative antiepileptic drugs, BIA 2–024 and BIA 2–093. Epilepsia (2004) 45(12):1498–1505.
   Google Scholar
• CHEUNG NS, KOH CH, BAY BH et al. : chronic exposure to U18666A induces apoptosis in cultured murine cortical neurons. Biochem. Biophys. Res. Commun. (2004) 315(2):408–417.
   PubMed Web of Science ®Google Scholar
• LANIGAN C, SURY M, BINGHAM R, HOWARD R, MACKERSIE A: Neurological sequelae in children after prolonged propofol infusion. Anaesthesia (1992) 47:810–811.
   PubMed Web of Science ®Google Scholar
• TROTTER C, SERPELL MG: Neurological sequelae in children after prolonged propofol infusion. Anaesthesia (1992) 47:340–342.
   PubMed Web of Science ®Google Scholar
• FINLEY GA, MACMANUS B, SAMPSON SE, FERNANDEZ CV, RETALLICK R: Delayed seizures following sedation with propofol. Can. J. Anaesth. (1993) 40:863–865.
   PubMed Web of Science ®Google Scholar
• MCFARLAN CS, ANDERSON BJ, SHORT TG: The use of propofol infusions in paediatric anaesthesia: a practical guide. Paediatr. Anaesth. (1999) 9(3):209–216.
   PubMedGoogle Scholar
• HONEGGER P, MATTHIEU JM: Selective toxicity of the general anesthetic propofol for GABAergic neurons in rat brain cell cultures. J. Neurosci. Res. (1996) 45:631–636.
   PubMed Web of Science ®Google Scholar
• LUBRICH B, VAN CALKER D: Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Neuropsychopharmacol. (1999) 21(4):519–529.
   Google Scholar
• CHEN G, MANJI HK, WRIGHT CB, HAWVER DB, POTTER WZ: Effects of valproic acid on β-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacol. (1996) 15:271–280.
   PubMed Web of Science ®Google Scholar
• CHEN G, HASANAT KA, BEBCHUK JM, MOORE GJ, GLITZ D, MANJI HK: Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosomatic Med. (1999) 61(5):599–617.
   PubMed Web of Science ®Google Scholar
• FIEBICH BL: Valproic acid inhibits substance P-induced activation of protein kinase C-ε and expression of the substance P receptor. J. Neurochem. (2003) 86(1):69–76.
   PubMed Web of Science ®Google Scholar
• WANG JF, AZZAM JE, YOUNG LT: Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neurosci. (2003) 116(2):485–489.
   PubMed Web of Science ®Google Scholar
• BOWDEN CL, JANICAK PG, ORSULAK P et al. : Relation of serum valproate concentration to response in mania. Am. J. Psychiatry (1996) 153(6):765–770.
   PubMed Web of Science ®Google Scholar
• FADEN AI, MOVSESYAN VA, KNOBLACH SM, AHMED F, CERNAK I: Neuroprotective effects of novel small peptides in vitro and after brain injury. Neuropharmacol. (2005) 19.
   Google Scholar
• ANDERSEN JK: Oxidative stress in neurodegeneration: cause or consequence. Nat. Med. (2004) 10:S18–S25.
   PubMed Web of Science ®Google Scholar
• VAIRANO M, GRAZIANI G, TENTORI L, TRINGALI G, NAVARRA P, DELLO RUSSO C: Primary cultures of microglial cells for testing toxicity of anticancer drugs. Toxicol. Lett. (2004) 148(1–2):91–94.
   Google Scholar
• COLE GM, MORIHARA T, LIM GP, YANG F, BEGUM A, RAUTSCHY SA: NSAID and antioxidant prevention of Alzheimer’s disease: lessons from in vitro and animal models. Ann. NY Acad. Sci. (2004) 1035:68–84.
   PubMed Web of Science ®Google Scholar
• GELDOF AA: Nerve-growth-factordependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy. J. Cancer Res. Clin. Oncol. (1995) 121:657–660.
   PubMed Web of Science ®Google Scholar
• HOL EM, MANDYS V, SODAAR P, GISPEN WH, BAR PR: Protection by an ACTH4–9 analogue against the toxic effects of cisplatin and taxol on sensory neurons and glial cells in vitro. J. Neurosci. Res. (1994) 39:178–185.
   PubMed Web of Science ®Google Scholar
• SANO M: Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons. Neuropharmacol. (2001) 40:947–953.
   PubMed Web of Science ®Google Scholar
• APFEL SC: Neurotrophic factors in peripheral neuropathies: therapeutical implications. Brain Pathol. (1999) 9:393–413.
   PubMed Web of Science ®Google Scholar
• VERSTAPPEN CC, GELDOF AA, POSTMA TJ, HEIMANS JJ: In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR-1065. J. Neurooncol. (1999) 44(1):1–5.
   PubMed Web of Science ®Google Scholar
• VERSTAPPEN CC, POSTMA TJ, GELDOF AA, HEIMANS JJ: Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation. Anti-Cancer Res. (2004) 24(4):2337–2341.
   PubMed Web of Science ®Google Scholar
• CAVALETTI G, TREDICI G, MARMIROLI P, PETRUCCIOLI MG, BARAJON I, FABBRICA D: Morphometric study of the sensory neurons and peripheral nerve changes induced by chronic cisplatin (DDP) administration. Acta Neuropathol. (1992) 84:364–371.
   PubMed Web of Science ®Google Scholar
• PISANO C, PRATESI G, LACCABUE D et al. : Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-Lcarnitine. Clin. Cancer. Res. (2003) 9:5756–5767.
   PubMed Web of Science ®Google Scholar
• DE SANTIS S, PACE A, BOVE L et al. : Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin. Cancer Res. (2000) 6:90–95.
   PubMed Web of Science ®Google Scholar
• CAVALETTI G, PEZZONI G, PISANO C, OGGIONI N, SALA F, ZOIA C: Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. Neurosci. Lett. (2002) 322:103–106.
   PubMed Web of Science ®Google Scholar
• TAGLIALATELA G, ANGELUCCI L, RAMACCI MT, WERRBACH-PEREZ K, JACKSON GF, PEREX-POLO R: Stimulation of nerve growth factor receptor in PC-12 cells by acetyl-L-carnitine. Biochem. Pharmacol. (1992) 44:577–585.
   PubMed Web of Science ®Google Scholar
• FISCHER SJ, PODRATZ JL, WINDEBANK AJ: Nerve growth factor rescue of cisplatin neurotoxicity is mediated through the high affinity receptor: studies in PC-12 cells and p75 null mouse dorsal root ganglia. Neurosci. Lett. (2001) 308:1–4.
   PubMed Web of Science ®Google Scholar
• MALGRANGE B, DELREE P, RIGO JM, BARON H, MOONEN G: Image analysis of neurite regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and its prevention by nerve growth factor or fibroblast growth factor, but not brain derived neurotrophic factor or neurotrophin-3. J. Neurosci. Meth. (1994) 53:111–122.
   PubMed Web of Science ®Google Scholar
• RADWAN IA, SAITO S, GOTO F: The neurotoxicity of local anesthetics on growing neurons: a comparative study of lidocaine, bupivacaine, mepivacaine and ropivacaine. Anesth. Analg. (2002) 94:319–324.
   PubMed Web of Science ®Google Scholar
• LIRK P, LONGATO S, RIEDER J, KLIMASCHEWSKI L: Cisatracurium, but not mivacurium, inhibits survival and axonal growth of neonatal and adult rat peripheral neurons in vitro. Neurosci. Lett. (2004) 365:153–155.
   Google Scholar
• BRAT DJ, BRIMIJOIN S: Acrylamide and glycidamide impair neurite outgrowth in differentiating N1E 115 neuroblastoma without disturbing rapid bidirectional transport of organelles observed by video microscopy. J. Neurochem. (1993) 60:2145–2152.
   PubMed Web of Science ®Google Scholar
• GARLE MJ, FRY JR: Sensory nerves, neurogenic inflammation and pain: missing components of alternative irritation strategies: a review and a potential strategy. Altern. Lab. Anim. (2003) 31(3):295–316.
   PubMed Web of Science ®Google Scholar
• KLEMM M, SCHRATTENHOLZ A: Neurotoxicity of active compounds - establishment of hESC-lines and proteomics technologies for human embryo-and neurotoxicity screening and biomarker identification. ALTEX (2004) 21(Suppl. 3):41–48.
   PubMedGoogle Scholar
• CONTI L, POLLARD SM, GORBA T et al. : Niche-independent symmetrical selfrenewal of a mammalian tissue stem cell. PLoS Biol. (2005) 3(9):e283.
   PubMedGoogle Scholar
• WOBUS AM, BOHELER KR: Embryonic stem cells: Prospects for developmental biology and cell therapy. Physiol. Rev. (2005) 85:635–678.
   PubMed Web of Science ®Google Scholar
• BUZANSKA L, HABICH A, JURGA M, SYPECKA J, DOMANSKA-JANIK K: Human cord blood-derived neural stem cell line - possible implementation in studying neurotoxicity. Toxicol. In Vitro (2005) 19(7):991–999.
   PubMed Web of Science ®Google Scholar
• MORSHEAD CM, BENVENISTE P, ISCOVE NN, VAN DER KOOY D: Hematopoietic competence is a rare property of neural stem cells that may depend on genetic and epigenetic alterations. Nat. Med. (2002) 8:268–273.
   PubMed Web of Science ®Google Scholar
• ROSSI F, CATTANEO E: Opinion: neural stem cell therapy for neurological disease: dreams and reality. Nat. Rev. Neurosci. 3:401–409.
   PubMed Web of Science ®Google Scholar
• BLAAUBOER BJ: The necessity of biokinetic information in the interpretation of in vitro toxicity data. Altern. Lab. Anim. (2002) 30(Suppl. 2):85–91.
   Google Scholar